Compare Stocks

5 / 10
Try these comparisons:

Stock Comparison

YI vs CRON vs HIMS vs CGC vs TDOC

Revenue, margins, valuation, and 5-year total return — side by side.

Live fundamentals10-year financials5-year price chart
YI
111, Inc.

Medical - Pharmaceuticals

HealthcareNASDAQ • CN
Market Cap$48M
5Y Perf.-92.5%
CRON
Cronos Group Inc.

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$981M
5Y Perf.-60.6%
HIMS
Hims & Hers Health, Inc.

Medical - Equipment & Services

HealthcareNYSE • US
Market Cap$6.63B
5Y Perf.+158.4%
CGC
Canopy Growth Corporation

Drug Manufacturers - Specialty & Generic

HealthcareNASDAQ • CA
Market Cap$122M
5Y Perf.-99.3%
TDOC
Teladoc Health, Inc.

Medical - Healthcare Information Services

HealthcareNYSE • US
Market Cap$1.26B
5Y Perf.-96.0%

YI vs CRON vs HIMS vs CGC vs TDOC — Key Financials

Market cap, revenue, margins, and valuation side-by-side.

Company Snapshot
YI logoYI
CRON logoCRON
HIMS logoHIMS
CGC logoCGC
TDOC logoTDOC
IndustryMedical - PharmaceuticalsDrug Manufacturers - Specialty & GenericMedical - Equipment & ServicesDrug Manufacturers - Specialty & GenericMedical - Healthcare Information Services
Market Cap$48M$981M$6.63B$122M$1.26B
Revenue (TTM)$14.18B$193M$2.35B$294M$2.51B
Net Income (TTM)$-74M$-9M$128M$-327M$-171M
Gross Margin5.0%32.5%69.7%22.8%65.6%
Operating Margin-0.0%-1.5%4.6%-24.1%-7.6%
Forward P/E34.3x51.5x
Total Debt$257M$2M$1.12B$348M$1.04B
Cash & Equiv.$462M$792M$229M$114M$781M

YI vs CRON vs HIMS vs CGC vs TDOCLong-Term Stock Performance

Price return indexed to 100 at period start. Dividends excluded.

YI
CRON
HIMS
CGC
TDOC
StockMay 20May 26Return
111, Inc. (YI)1007.5-92.5%
Cronos Group Inc. (CRON)10039.4-60.6%
Hims & Hers Health,… (HIMS)100258.4+158.4%
Canopy Growth Corpo… (CGC)1000.7-99.3%
Teladoc Health, Inc. (TDOC)1004.0-96.0%

Price return only. Dividends and distributions are not included.

Quick Verdict: YI vs CRON vs HIMS vs CGC vs TDOC

Each card shows where this stock fits in a portfolio — not just who wins on paper.

Bottom line: CRON leads in 3 of 7 categories (5-stock set), making it the strongest pick for growth and revenue expansion and valuation and capital efficiency. Hims & Hers Health, Inc. is the stronger pick specifically for profitability and margin quality and operational efficiency and capital deployment. YI also leads in specific categories worth noting. As sector peers, any of these can serve as alternatives in the same allocation.
YI
111, Inc.
The Income Pick

YI ranks third and is worth considering specifically for income & stability.

  • beta 0.29
  • Beta 0.29 vs HIMS's 2.40, lower leverage
Best for: income & stability
CRON
Cronos Group Inc.
The Growth Play

CRON carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.

  • Rev growth 64.4%, EPS growth -100.0%, 3Y rev CAGR 30.6%
  • 14.6% 10Y total return vs HIMS's 161.9%
  • Lower volatility, beta 0.98, Low D/E 0.1%, current ratio 19.59x
  • Beta 0.98, current ratio 19.59x
Best for: growth exposure and long-term compounding
HIMS
Hims & Hers Health, Inc.
The Quality Compounder

HIMS is the #2 pick in this set and the best alternative if quality and efficiency is your priority.

  • 5.5% margin vs CGC's -111.0%
  • 6.0% ROA vs CGC's -29.5%, ROIC 10.7% vs -10.2%
Best for: quality and efficiency
CGC
Canopy Growth Corporation
The Healthcare Pick

CGC lags the leaders in this set but could rank higher in a more targeted comparison.

Best for: healthcare exposure
TDOC
Teladoc Health, Inc.
The Healthcare Pick

Among these 5 stocks, TDOC doesn't own a clear edge in any measured category.

Best for: healthcare exposure
See the full category breakdown
CategoryWinnerWhy
GrowthCRON logoCRON64.4% revenue growth vs CGC's -9.5%
ValueCRON logoCRONBetter valuation composite
Quality / MarginsHIMS logoHIMS5.5% margin vs CGC's -111.0%
Stability / SafetyYI logoYIBeta 0.29 vs HIMS's 2.40, lower leverage
DividendsTieNone of these 5 stocks pay a meaningful dividend
Momentum (1Y)CRON logoCRON+38.9% vs HIMS's -51.0%
Efficiency (ROA)HIMS logoHIMS6.0% ROA vs CGC's -29.5%, ROIC 10.7% vs -10.2%

YI vs CRON vs HIMS vs CGC vs TDOC — Revenue Breakdown by Segment

How each company's revenue is distributed across its business units

YI111, Inc.
FY 2024
Product
49.6%$14.3B
Drugs
46.5%$13.4B
Nutritional Supplements
1.9%$550M
Other Products
0.7%$202M
Medical Supplies And Devices
0.5%$144M
Service
0.4%$107M
MP Service
0.2%$66M
Other (1)
0.1%$41M
CRONCronos Group Inc.
FY 2025
Cannabis Flower
74.0%$108M
Cannabis Extracts
25.7%$38M
Product and Service, Other
0.3%$411,000
HIMSHims & Hers Health, Inc.

Segment breakdown not available.

CGCCanopy Growth Corporation
FY 2024
Canadian Cannabis Net Revenue
57.9%$156M
Storz And Bickel
27.3%$73M
International And Other Revenue
14.8%$40M
Other Revenue
0.0%$0
TDOCTeladoc Health, Inc.
FY 2025
Other
100.0%$438M

YI vs CRON vs HIMS vs CGC vs TDOC — Financial Metrics

Side-by-side numbers across 5 stocks — who leads on profitability, valuation, growth, and risk.

BEST OVERALLHIMSLAGGINGTDOC

Income & Cash Flow (Last 12 Months)

HIMS leads this category, winning 3 of 6 comparable metrics.

YI is the larger business by revenue, generating $14.2B annually — 73.4x CRON's $193M. HIMS is the more profitable business, keeping 5.5% of every revenue dollar as net income compared to CGC's -111.0%. On growth, CRON holds the edge at +2.0% YoY revenue growth, suggesting stronger near-term business momentum.

MetricYI logoYI111, Inc.CRON logoCRONCronos Group Inc.HIMS logoHIMSHims & Hers Healt…CGC logoCGCCanopy Growth Cor…TDOC logoTDOCTeladoc Health, I…
RevenueTrailing 12 months$14.2B$193M$2.3B$294M$2.5B
EBITDAEarnings before interest/tax$11M-$810,000$164M-$32M$42M
Net IncomeAfter-tax profit-$74M-$9M$128M-$327M-$171M
Free Cash FlowCash after capex$97M-$163,766$73M-$86M$251M
Gross MarginGross profit ÷ Revenue+5.0%+32.5%+69.7%+22.8%+65.6%
Operating MarginEBIT ÷ Revenue-0.0%-1.5%+4.6%-24.1%-7.6%
Net MarginNet income ÷ Revenue-0.5%-4.9%+5.5%-111.0%-6.8%
FCF MarginFCF ÷ Revenue+0.7%-0.1%+3.1%-29.3%+10.0%
Rev. Growth (YoY)Latest quarter vs prior year-6.4%+2.0%+28.4%+20.9%-2.5%
EPS Growth (YoY)Latest quarter vs prior year-36.6%-100.0%-27.3%+83.8%+32.1%
HIMS leads this category, winning 3 of 6 comparable metrics.

Valuation Metrics

YI leads this category, winning 3 of 6 comparable metrics.

On an enterprise value basis, YI's 6.4x EV/EBITDA is more attractive than HIMS's 42.7x.

MetricYI logoYI111, Inc.CRON logoCRONCronos Group Inc.HIMS logoHIMSHims & Hers Healt…CGC logoCGCCanopy Growth Cor…TDOC logoTDOCTeladoc Health, I…
Market CapShares × price$48M$981M$6.6B$122M$1.3B
Enterprise ValueMkt cap + debt − cash$18M$190M$7.5B$293M$1.5B
Trailing P/EPrice ÷ TTM EPS-5.05x50.32x-0.28x-6.11x
Forward P/EPrice ÷ next-FY EPS est.34.27x51.51x
PEG RatioP/E ÷ EPS growth rate
EV / EBITDAEnterprise value multiple6.38x42.68x15.13x
Price / SalesMarket cap ÷ Revenue0.02x5.07x2.82x0.62x0.50x
Price / BookPrice ÷ Book value/share0.86x0.90x12.25x0.34x0.89x
Price / FCFMarket cap ÷ FCF1.32x89.61x4.40x
YI leads this category, winning 3 of 6 comparable metrics.

Profitability & Efficiency

HIMS leads this category, winning 4 of 9 comparable metrics.

HIMS delivers a 23.7% return on equity — every $100 of shareholder capital generates $24 in annual profit, vs $-43 for CGC. CRON carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to HIMS's 2.07x. On the Piotroski fundamental quality scale (0–9), YI scores 7/9 vs HIMS's 4/9, reflecting strong financial health.

MetricYI logoYI111, Inc.CRON logoCRONCronos Group Inc.HIMS logoHIMSHims & Hers Healt…CGC logoCGCCanopy Growth Cor…TDOC logoTDOCTeladoc Health, I…
ROE (TTM)Return on equity-21.4%-0.9%+23.7%-43.1%-12.4%
ROA (TTM)Return on assets-2.7%-0.8%+6.0%-29.5%-5.9%
ROICReturn on invested capital+1.1%-0.8%+10.7%-10.2%-11.5%
ROCEReturn on capital employed+0.5%-0.3%+10.9%-12.4%-10.0%
Piotroski ScoreFundamental quality 0–976456
Debt / EquityFinancial leverage0.67x0.00x2.07x0.72x0.75x
Net DebtTotal debt minus cash-$206M-$790M$892M$235M$259M
Cash & Equiv.Liquid assets$462M$792M$229M$114M$781M
Total DebtShort + long-term debt$257M$2M$1.1B$348M$1.0B
Interest CoverageEBIT ÷ Interest expense-0.05x-7.79x-8.76x
HIMS leads this category, winning 4 of 9 comparable metrics.

Total Returns (Dividends Reinvested)

HIMS leads this category, winning 3 of 6 comparable metrics.

A $10,000 investment in HIMS five years ago would be worth $23,764 today (with dividends reinvested), compared to $45 for CGC. Over the past 12 months, CRON leads with a +38.9% total return vs HIMS's -51.0%. The 3-year compound annual growth rate (CAGR) favors HIMS at 29.4% vs CGC's -55.9% — a key indicator of consistent wealth creation.

MetricYI logoYI111, Inc.CRON logoCRONCronos Group Inc.HIMS logoHIMSHims & Hers Healt…CGC logoCGCCanopy Growth Cor…TDOC logoTDOCTeladoc Health, I…
YTD ReturnYear-to-date+102.2%-4.8%-23.2%-5.0%-1.3%
1-Year ReturnPast 12 months-25.4%+38.9%-51.0%-12.4%+1.5%
3-Year ReturnCumulative with dividends-79.9%+29.1%+116.6%-91.4%-73.3%
5-Year ReturnCumulative with dividends-95.1%-66.6%+137.6%-99.6%-95.4%
10-Year ReturnCumulative with dividends-96.0%+1457.6%+161.9%-94.3%-41.1%
CAGR (3Y)Annualised 3-year return-41.4%+8.9%+29.4%-55.9%-35.6%
HIMS leads this category, winning 3 of 6 comparable metrics.

Risk & Volatility

Evenly matched — YI and CRON each lead in 1 of 2 comparable metrics.

YI is the less volatile stock with a 0.29 beta — it tends to amplify market swings less than HIMS's 2.40 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. CRON currently trades 74.9% from its 52-week high vs HIMS's 36.4% drawdown — a narrower gap to the peak suggests stronger recent price momentum.

MetricYI logoYI111, Inc.CRON logoCRONCronos Group Inc.HIMS logoHIMSHims & Hers Healt…CGC logoCGCCanopy Growth Cor…TDOC logoTDOCTeladoc Health, I…
Beta (5Y)Sensitivity to S&P 5000.29x0.98x2.40x1.90x1.91x
52-Week HighHighest price in past year$11.17$3.43$70.43$2.38$9.77
52-Week LowLowest price in past year$2.48$1.84$13.74$0.84$4.40
% of 52W HighCurrent price vs 52-week peak+50.0%+74.9%+36.4%+47.5%+71.2%
RSI (14)Momentum oscillator 0–10031.149.354.552.974.1
Avg Volume (50D)Average daily shares traded13K1.4M34.9M10.4M5.5M
Evenly matched — YI and CRON each lead in 1 of 2 comparable metrics.

Analyst Outlook

Insufficient data to determine a leader in this category.

Analyst consensus: CRON as "Hold", HIMS as "Hold", CGC as "Hold", TDOC as "Hold". Consensus price targets imply 1180.5% upside for CGC (target: $14) vs -10.5% for CRON (target: $2).

MetricYI logoYI111, Inc.CRON logoCRONCronos Group Inc.HIMS logoHIMSHims & Hers Healt…CGC logoCGCCanopy Growth Cor…TDOC logoTDOCTeladoc Health, I…
Analyst RatingConsensus buy/hold/sellHoldHoldHoldHold
Price TargetConsensus 12-month target$2.30$29.67$14.47$7.58
# AnalystsCovering analysts15192642
Dividend YieldAnnual dividend ÷ price
Dividend StreakConsecutive years of raises
Dividend / ShareAnnual DPS
Buyback YieldShare repurchases ÷ mkt cap0.0%+1.0%+1.4%0.0%0.0%
Insufficient data to determine a leader in this category.
Key Takeaway

HIMS leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). YI leads in 1 (Valuation Metrics). 1 tied.

Best OverallHims & Hers Health, Inc. (HIMS)Leads 3 of 6 categories
Loading custom metrics...

YI vs CRON vs HIMS vs CGC vs TDOC: Key Questions Answered

10 questions · data-driven answers · updated daily

01

Is YI or CRON or HIMS or CGC or TDOC a better buy right now?

For growth investors, Cronos Group Inc.

(CRON) is the stronger pick with 64. 4% revenue growth year-over-year, versus -9. 5% for Canopy Growth Corporation (CGC). Hims & Hers Health, Inc. (HIMS) offers the better valuation at 50. 3x trailing P/E (51. 5x forward), making it the more compelling value choice. Analysts rate Cronos Group Inc. (CRON) a "Hold" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

02

Which has the better valuation — YI or CRON or HIMS or CGC or TDOC?

On forward P/E, Cronos Group Inc.

is actually cheaper at 34. 3x — notably different from the trailing picture, reflecting expected earnings growth.

03

Which is the better long-term investment — YI or CRON or HIMS or CGC or TDOC?

Over the past 5 years, Hims & Hers Health, Inc.

(HIMS) delivered a total return of +137. 6%, compared to -99. 6% for Canopy Growth Corporation (CGC). Over 10 years, the gap is even starker: CRON returned +1458% versus YI's -96. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

04

Which is safer — YI or CRON or HIMS or CGC or TDOC?

By beta (market sensitivity over 5 years), 111, Inc.

(YI) is the lower-risk stock at 0. 29β versus Hims & Hers Health, Inc. 's 2. 40β — meaning HIMS is approximately 724% more volatile than YI relative to the S&P 500. On balance sheet safety, Cronos Group Inc. (CRON) carries a lower debt/equity ratio of 0% versus 2% for Hims & Hers Health, Inc. — giving it more financial flexibility in a downturn.

05

Which is growing faster — YI or CRON or HIMS or CGC or TDOC?

By revenue growth (latest reported year), Cronos Group Inc.

(CRON) is pulling ahead at 64. 4% versus -9. 5% for Canopy Growth Corporation (CGC). On earnings-per-share growth, the picture is similar: 111, Inc. grew EPS 83. 9% year-over-year, compared to -100. 0% for Cronos Group Inc.. Over a 3-year CAGR, HIMS leads at 64. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

06

Which has better profit margins — YI or CRON or HIMS or CGC or TDOC?

Hims & Hers Health, Inc.

(HIMS) is the more profitable company, earning 5. 5% net margin versus -222. 4% for Canopy Growth Corporation — meaning it keeps 5. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HIMS leads at 5. 2% versus -43. 5% for CGC. At the gross margin level — before operating expenses — TDOC leads at 69. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

07

Is YI or CRON or HIMS or CGC or TDOC more undervalued right now?

On forward earnings alone, Cronos Group Inc.

(CRON) trades at 34. 3x forward P/E versus 51. 5x for Hims & Hers Health, Inc. — 17. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for CGC: 1180. 5% to $14. 47.

08

Which pays a better dividend — YI or CRON or HIMS or CGC or TDOC?

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

09

Is YI or CRON or HIMS or CGC or TDOC better for a retirement portfolio?

For long-horizon retirement investors, Cronos Group Inc.

(CRON) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 98), +1458% 10Y return). Canopy Growth Corporation (CGC) carries a higher beta of 1. 90 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (CRON: +1458%, CGC: -94. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

10

What are the main differences between YI and CRON and HIMS and CGC and TDOC?

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: YI is a small-cap quality compounder stock; CRON is a small-cap high-growth stock; HIMS is a small-cap high-growth stock; CGC is a small-cap quality compounder stock; TDOC is a small-cap quality compounder stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.

Find Stocks Like These

Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform all of them.

Stocks Like

YI

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
Run This Screen
Stocks Like

CRON

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 100%
  • Gross Margin > 19%
Run This Screen
Stocks Like

HIMS

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 14%
  • Net Margin > 5%
Run This Screen
Stocks Like

CGC

High-Growth Disruptor

  • Sector: Healthcare
  • Market Cap > $100B
  • Revenue Growth > 10%
  • Gross Margin > 13%
Run This Screen
Stocks Like

TDOC

Quality Business

  • Sector: Healthcare
  • Market Cap > $100B
  • Gross Margin > 39%
Run This Screen
Custom Screen

Beat Both

Find stocks that outperform YI and CRON and HIMS and CGC and TDOC on the metrics below

Revenue Growth>
%
(YI: -6.4% · CRON: 201.3%)

You Might Also Compare

Based on how these companies actually compete and overlap — not just which sector they're filed under.